Psychopharmacology

, Volume 90, Issue 4, pp 468–470

Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance

Authors

  • Michael W. Jann
    • College of PharmacyThe University of Texas at Austin
    • Department of PharmacologyThe University of Texas Health Science Center at San Antonio
    • San Antonio State School
  • Stephen R. Saklad
    • College of PharmacyThe University of Texas at Austin
    • Department of PharmacologyThe University of Texas Health Science Center at San Antonio
    • Department of PsychiatryThe University of Texas Health Science Center at San Antonio
    • San Antonio State Hospital
  • Larry Ereshefsky
    • College of PharmacyThe University of Texas at Austin
    • Department of PharmacologyThe University of Texas Health Science Center at San Antonio
    • Department of PsychiatryThe University of Texas Health Science Center at San Antonio
    • San Antonio State Hospital
  • Ann L. Richards
    • College of PharmacyThe University of Texas at Austin
    • San Antonio State Hospital
  • Charles A. Harrington
    • Department of PsychiatryUniversity of Texas Mental Science Institute
  • Chester M. Davis
    • Department of PsychiatryUniversity of Texas Mental Science Institute
Original Investigations

DOI: 10.1007/BF00174062

Cite this article as:
Jann, M.W., Saklad, S.R., Ereshefsky, L. et al. Psychopharmacology (1986) 90: 468. doi:10.1007/BF00174062

Abstract

Plasma concentrations of haloperidol and its reduced metabolite (reduced haloperidol) were investigated in cigarette smokers (N=23) and nonsmokers (N=27). Steady-state plasma concentrations were obtained 12 h post bedtime dose. Haloperidol and reduced haloperidol concentrations were determined by RIA. Reduced haloperidol was separated by selective succinylation and liquid chromatography. Patients were clinically assessed with the Clinical Global Impression Scale (CGIS). Smokers had significantly lower haloperidol and reduced haloperidol plasma concentrations than nonsmokers (P<0.01, P<0.05). Clearance of haloperidol was significantly greater in smokers compared to nonsmokers (P=0.0052). CGIS assessments did not show significant differences between smokers and non-smokers. Plasma concentrations should be carefully monitored when patients either start or stop smoking.

Key words

SmokingHaloperidolReduced haloperidolPlasma concentrationsClearance

Copyright information

© Springer-Verlag 1986